A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan
Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Contact Backup
- Name: First line of the email MUST contain NCT # and Site #.
Study Locations
-
-
Tokyo
-
Minato-ku, Tokyo, Japan, 1050001
- Local Institution - 0001
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria - hypertrophic cardiomyopathy group
- Participants diagnosed with non-obstructive or obstructive HCM in Japan
- Participants aged ≥18 years of age
- Participants who have been attending outpatient visits for HCM and who are referred to the study by the physician treating HCM
- Participants with HCM who are diagnosed as New York Heart Association (NYHA) functional classification 2-3 at enrolment
- Participants experiencing burden in their daily lives because of HCM (self-reported)
Inclusion Criteria - control group
- Participants aged ≥18 years of age
- Individuals from the general population who are enrolled in 3H Clinical Trial's consumer panel
Exclusion Criteria - hypertrophic cardiomyopathy group
- Participants who have ever been diagnosed with dilated cardiomyopathy or secondary cardiomyopathy, including cardiac amyloidosis, Fabry disease, or mitochondrial myopathy
- Participants who have previously participated or are currently participating in another clinical trial (not including observational studies)
Exclusion Criteria - control group
- Participants who have ever been diagnosed with non-obstructive or obstructive HCM
- Participants who have ever been diagnosed with either dilated cardiomyopathy or secondary cardiomyopathy, including cardiac amyloidosis, Fabry disease, or mitochondrial myopathy
- Participants who have previously participated or are currently participating in another clinical trial (not including observational studies)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Control group
|
Quality of life assessment
|
|
Participants diagnosed with non-obstructive hypertrophic cardiomyopathy
|
Quality of life assessment
|
|
Participants diagnosed with obstructive hypertrophic cardiomyopathy
|
Quality of life assessment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participant age
Time Frame: Baseline
|
Baseline
|
|
|
Participant sex
Time Frame: Baseline
|
Baseline
|
|
|
Participant employment status
Time Frame: Baseline
|
Baseline
|
|
|
Participant height
Time Frame: Baseline
|
Baseline
|
|
|
Participant weight
Time Frame: Baseline
|
Baseline
|
|
|
Participant smoking status
Time Frame: Baseline
|
Baseline
|
|
|
Participant drinking status
Time Frame: Baseline
|
Baseline
|
|
|
Family members co-residing with participant
Time Frame: Baseline
|
Baseline
|
|
|
Participant comorbidities
Time Frame: Baseline
|
Baseline
|
|
|
Participant mental disorders under current medical treatment
Time Frame: Baseline
|
Baseline
|
|
|
Time from first diagnosis of mental disorders
Time Frame: Baseline
|
Baseline
|
|
|
Family history of hypertrophic cardiomyopathy (HCM) in participants with diagnosed HCM
Time Frame: Baseline
|
Baseline
|
|
|
Period from first diagnosis of hypertrophic cardiomyopathy (HCM) in participants with diagnosed HCM
Time Frame: Baseline
|
Baseline
|
|
|
New York Heart Association functional classification (self-reported) in participants with diagnosed hypertrophic cardiomyopathy
Time Frame: Baseline
|
Baseline
|
|
|
History of non-drug therapy in participants with diagnosed hypertrophic cardiomyopathy
Time Frame: Baseline
|
Percutaneous transluminal septal myocardial ablation, pacing therapy, other surgical therapies
|
Baseline
|
|
Participant need for support/caregivers in participants with diagnosed hypertrophic cardiomyopathy
Time Frame: Baseline
|
Baseline
|
|
|
Participant current medications for hypertrophic cardiomyopathy in participants with diagnosed with HCM
Time Frame: Baseline
|
Baseline
|
|
|
Patient-reported health-related quality of life assessed by using the European Quality of Life 5 Dimension 5 Level (EQ-5D-5L) questionnaire
Time Frame: Baseline
|
EQ-5D-5L consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with five levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.
The total score ranges from -0.025 to 1, and higher scores reflect better health status.
|
Baseline
|
|
Patient-reported health-related quality of life assessed by using the Hospital Anxiety Depression Scale (HADS)
Time Frame: Baseline
|
HADS is an anxiety and depression assessment scale consisting of seven items (rated 0, 1, 2, or 3) related to anxiety (subscale A) and seven other items related to depression (subscale D).
The total score ranges from 0 to 14, and higher scores reflect a worse health status.
|
Baseline
|
|
Patient-reported health-related quality of life assessed by using the Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time Frame: Baseline
|
The KCCQ is a 23-item questionnaire developed to assess HRQoL in patients with congestive heart failure.
The KCCQ consists of five domains: physical limitation, symptoms (frequency, severity, and recent change over time), QoL, social interference, and self-efficacy.
The total score ranges from 0 to 100, and higher scores reflect better health status.
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CV027-1141
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.